Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jul 2025 According to a Lutris Pharma media release, date from this study were presented in an oral presentation at the Clinical Trials Plenary Session at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025.
07 Jul 2025 Results presented in the Lutris Pharma Media Release.
17 Jun 2025 According to a Lutris Pharma media release, announced the presentation data will be released in an oral presentation during a Proffered Paper Session at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, being held July 2-5 in Barcelona, Spain.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com